Clinical trials for Multiple myeloma
62 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT05020236
#2023-509208-14-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT06158841
#2023-506668-15-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Abbvie
Phase 3
Multiple myeloma
#NCT06561854
#2024-510981-18-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
1 recruiting site
Assistance Publique - Hôpitaux de Paris
Phase 2 / Phase 3
Multiple myeloma
#NCT07095452
#2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT06140524
#2023-505242-25-00
Required histologic types
Smoldering multiple myeloma (SMM)
Monoclonal gammopathy of undetermined significance...
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Regeneron Pharmaceuticals
Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
Multiple myeloma
#NCT04935684
Required histologic types
B cell lymphoma
T cell lymphoma
Hodgkin lymphoma
CLL (Chronic Lymphocytic Leukemia)
Symptomatic multiple myeloma
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CHU de Clermont-Ferrand
Phase 2
Multiple myeloma
#NCT06183489
#2023-505775-70-00
Required histologic types
Smoldering multiple myeloma (SMM)
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
6 recruiting sites
European Myeloma Network B.V.